SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Aclaris Therapeutics, Inc. (ACRS)

ACRS RSS Feed
Add ACRS Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/6/2016 11:44:47 AM - Followers: 1 - Board type: Free - Posts Today: 0

Aclaris Therapeutics, Inc. 101 Lindenwood Drive Suite 400 Malvern, PA 19355 United States 484-324-7933 http://www.aclaristx.com Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACRS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ACRS News: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Soluti... 04/26/2017 07:00:00 AM
ACRS News: Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting 04/24/2017 08:00:00 AM
ACRS News: Current Report Filing (8-k) 04/21/2017 04:18:43 PM
ACRS News: Proxy Statement (definitive) (def 14a) 04/21/2017 04:11:48 PM
ACRS News: Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Res... 04/04/2017 08:00:00 AM
PostSubject
#1   ACRS bullish 22.07 stocktrademan 09/06/16 11:44:47 AM
PostSubject